Cargando…

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells

BRAF(V600E) is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonaldi, Elisa, Gargiuli, Chiara, De Cecco, Loris, Micali, Arianna, Rizzetti, Maria Grazia, Greco, Angela, Borrello, Maria Grazia, Minna, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198461/ https://www.ncbi.nlm.nih.gov/pubmed/34072194 http://dx.doi.org/10.3390/ijms22115744

Ejemplares similares

The molecular and gene/miRNA expression profiles of radioiodine resistant papillary thyroid cancer
por: Colombo, Carla, et al.
Publicado: (2020)

Genomic and transcriptomic analyses of thyroid cancers identify DICER1 somatic mutations in adult follicular-patterned RAS-like tumors
por: Minna, Emanuela, et al.
Publicado: (2023)

The modifier role of RET-G691S polymorphism in hereditary medullary thyroid carcinoma: functional characterization and expression/penetrance studies
por: Colombo, Carla, et al.
Publicado: (2015)

Senescent Thyrocytes, Similarly to Thyroid Tumor Cells, Elicit M2-like Macrophage Polarization In Vivo
por: Mazzoni, Mara, et al.
Publicado: (2021)

Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples
por: Minna, Emanuela, et al.
Publicado: (2022)

Senescent thyrocytes and thyroid tumor cells induce M2-like macrophage polarization of human monocytes via a PGE2-dependent mechanism
por: Mazzoni, Mara, et al.
Publicado: (2019)

Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma
por: Minna, Emanuela, et al.
Publicado: (2020)

miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2016)

Correction: miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2018)

miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma
por: Minna, Emanuela, et al.
Publicado: (2014)

A Cross-Comparison of High-Throughput Platforms for Circulating MicroRNA Quantification, Agreement in Risk Classification, and Biomarker Discovery in Non-Small Cell Lung Cancer
por: Gargiuli, Chiara, et al.
Publicado: (2022)

Transmission of SARS-CoV-2 in Surgical Smoke during Laparoscopy: A Prospective, Proof-of-concept Study
por: Bogani, Giorgio, et al.
Publicado: (2021)

Peritoneal fluid COVID-19 testing in patients with a negative nasopharyngeal swab: prospective study
por: Licata, Armando G, et al.
Publicado: (2023)

Different Molecular Phenotypes of Progression in BRAF- and RAS-Like Papillary Thyroid Carcinoma
por: Lim, Jinsun, et al.
Publicado: (2023)

SARS-CoV-2 Serology Monitoring of a Cancer Center Staff in the Pandemic Most Infected Italian Region
por: Ciniselli, Chiara Maura, et al.
Publicado: (2021)

Aberrantly methylated genes in human papillary thyroid cancer and their association with BRAF/RAS mutation
por: Kikuchi, Yasuko, et al.
Publicado: (2013)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved
por: Vizioli, Maria Grazia, et al.
Publicado: (2014)

Role of VEGFR‐1 in melanoma acquired resistance to the BRAF inhibitor vemurafenib
por: Atzori, Maria Grazia, et al.
Publicado: (2019)

Integrated Ligand-Receptor Bioinformatic and In Vitro Functional Analysis Identifies Active TGFA/EGFR Signaling Loop in Papillary Thyroid Carcinomas
por: Degl'Innocenti, Debora, et al.
Publicado: (2010)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

Correction: Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved
por: Vizioli, Maria Grazia, et al.
Publicado: (2022)

Frequency and Significance of Ras, Tert Promoter, and Braf Mutations in Cytologically Indeterminate Thyroid Nodules: A Monocentric Case Series at a Tertiary-Level Endocrinology Unit
por: Censi, Simona, et al.
Publicado: (2017)

TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases
por: Insilla, Andrea Cacciato, et al.
Publicado: (2018)

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
por: Bronte, Enrico, et al.
Publicado: (2015)

A dual mechanism of activation of the Sonic Hedgehog pathway in anaplastic thyroid cancer: crosstalk with RAS-BRAF-MEK pathway and ligand secretion by tumor stroma
por: Parascandolo, Alessia, et al.
Publicado: (2017)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer
por: Guarini, Chiara, et al.
Publicado: (2021)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells
por: Arozarena, Imanol, et al.
Publicado: (2014)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
por: Zhao, Yiqing, et al.
Publicado: (2021)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding
por: Martinez Fiesco, Juliana A., et al.
Publicado: (2022)

Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
por: Trebino, Tarah, et al.
Publicado: (2023)

BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
por: Oikonomou, Eftychia, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_df76ltse08u34fmqqst3trge7f